Updated on 15 July 2013
Jiangchuan Pharmaceutical, 87 percent of which is owned by Tianyin Pharmaceutical (TPI), aims to make it big in the antibiotic market of Bangladesh, India, and Pakistan
Singapore: Tianyin Pharmaceutical (TPI), China-based pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), and branded generics, plans to leverage on the antibiotic market of Bangladesh, India, and Pakistan with its new manufacturing capacity.
Jiangchuan Pharmaceutical, 87 percent of which is owned by TPI, is set to produce API of macrolide antibiotics in 240 ton annual capacity. The company has completed construction and GMP certification in 2011 and is operating since second half of 2012, primarily supporting TPI's Azithromycin tablets.
Headquartered at Chengdu, China, TPI specializes in development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list and 10 are included in the essential drug list of China.